

# Beta-Adrenoceptor Expression in Human Fat Cells from Different Regions

Peter Arner,\*<sup>||</sup> Lena Hellström,\*<sup>§</sup> Hans Wahrenberg,\* and Mikael Brönnegård\*<sup>§</sup>

\*Departments of Medicine,<sup>§</sup> Pediatrics,<sup>§</sup> Medical Nutrition, and the <sup>||</sup> Research Center Huddinge Hospital, S-141 86 Huddinge, Sweden

## Abstract

The expression of beta-adrenoceptors (BAR) was investigated in abdominal and gluteal fat cells of 32 nonobese men and women using radioligand binding and RNA excess solution hybridization. In both sexes the number of BAR binding sites was about twice as high in abdominal as in gluteal fat cells ( $P < 0.01$ ). Northern blot analysis of total RNA from adipose tissue showed hybridization of the BAR<sub>1</sub> probe to an mRNA species of about 2.5 kb and of the BAR<sub>2</sub> probe to an mRNA species of ~ 2.2 kb. The steady-state mRNA levels of BAR 1 and BAR 2 were also about twice as high in abdominal as in gluteal adipocytes of men and women ( $P < 0.01$ ). In abdominal fat cells the mRNA levels were ~ 45 and 30 molecules/cell for BAR<sub>1</sub> and BAR<sub>2</sub>, respectively. There were no regional or sex variations in BAR 1 and BAR 2 mRNA stability. The apparent half-life of mRNA for both receptor subtypes was ~ 6 h in both regions. The mRNA levels for beta actin did not differ between the two regions in either sex. Thus, differences in expression of the genes encoding for BAR 1 and BAR 2 can explain why abdominal fat cells have more BAR than gluteal fat cells. This variation in gene expression may be a molecular mechanism underlying the well known regional differences in catecholamine-induced lipolysis activity between central and peripheral adipose tissue. (*J. Clin. Invest.* 1990. 86:1595–1600.) Key words: beta-adrenoceptors • mRNA • catecholamines

## Introduction

Catecholamines are the major lipolysis-promoting hormones in adult human fat cells (1). This effect is mediated by beta-adrenoceptors (BAR).<sup>1</sup> In human fat cells, unlike in adipocytes from most other species, catecholamines also have antilipolytic properties that are mediated by alpha<sub>2</sub>-adrenoceptors. It is well established that there are marked regional variations in catecholamine-induced lipolysis; the hormones are much more lipolytic in abdominal than in gluteal/femoral human adipocytes (2–5). It has been suggested that site variations in lipolysis may be of importance for the difference in body fat distribution in men and in women and for the development of different types of regional obesity (6–8).

Address correspondence and reprint requests to Dr. Peter Arner, Department of Medicine, Huddinge Hospital, S-141 86 Huddinge, Sweden.

Received for publication 27 February 1990 and in revised form 5 June 1990.

1. Abbreviations used in this paper: BAR, beta-adrenoceptors; <sup>3</sup>HCGP, [5,7-<sup>3</sup>H]benzimidazole-2-1 hydrochloride; <sup>125</sup>I-CYP, <sup>125</sup>I-cyanopindolol; TNA, total nucleic acids.

The mechanisms underlying regional variations in lipolysis have been partly elucidated (9). It appears that an increase in the number of BAR (with normal affinity and normal coupling to lipolysis) is the major factor underlying an enhanced lipolytic effect of catecholamines in abdominal as compared with gluteal human fat cells. This may involve both BAR subtypes. The existence of BAR 1 and BAR 2 has been demonstrated in isolated human fat cells (10), and both receptor subtypes are coupled to lipolysis (11).

The factors responsible for variations in BAR content between fat cells from different adipose deposits are not known. Differences in gene expression, mRNA/protein processing, or protein degradation may be involved. In this study, we have investigated whether variations in BAR number between fat cells from different regions also involve differences in expression of the genes encoding for BAR 1 and BAR 2. Thus, steady-state mRNA levels for these two genes, as well as mRNA stability, were determined in abdominal and gluteal fat cells. mRNA was measured using solution hybridization techniques. The findings with mRNA have been related to cell surface BAR content in the adipocytes, which was determined by radioligand binding techniques.

## Methods

**Subjects.** 32 healthy volunteers (17 men and 15 women) participated in the study. They were all drug free. None of the women had taken oral contraceptives during the preceding 6-mo period. Their ages were 23–55 yr (mean±SE:33±2 yr). All were of normal weight and the body mass index was 24.0±0.3 kg/m<sup>2</sup>. All subjects gave their informed consent and the study was approved by the Ethics Committee of Huddinge Hospital. After the subjects had fasted overnight, one subcutaneous specimen (2–3 g) was excised from the infraumbilical region (abdominal site) and one from the upper lateral quadrant of the gluteal region under local anesthesia, as described previously (9). A part of the tissue was immediately frozen in liquid nitrogen and stored at -70°C. Fat cells were isolated from the remaining part as described previously (12). Some of these cells were frozen and stored as above. The remaining cells were used for receptor binding, as described below.

**Receptor binding assays.** Incubations were carried out under steady-state conditions, as described in detail elsewhere (12). Briefly, ~ 20,000 fat cells were incubated in triplicate at 37°C in 1 ml of Krebs-Ringer phosphate buffer (pH 7.4) containing 5 g/liter bovine serum albumin, 1 g/liter glucose, and 0.1 g/liter ascorbic acid plus radioligands.

In most of the experiments one low and one high concentration of radioligand was used. It was possible to perform complete saturation experiments in only six of the subjects because the amounts of adipose tissue available were limited. The hydrophobic antagonist <sup>125</sup>I-cyanopindolol (<sup>125</sup>I-CYP) was used in the saturation experiments and the hydrophilic antagonist (±) -4(3-butylamino-2-hydroxypropoxy) - [5,7-<sup>3</sup>H]benzimidazole-2-1 hydrochloride (<sup>3</sup>HCGP) was used in the other experiments. We have repeatedly shown (9, 13) that these radioligands bind to a single class of homogeneous, noninteracting binding sites that give straight lines on a Scatchard analysis and Hill coefficients near 1. Under such conditions, the use of two radioligand concentrations to determine antagonist-binding capacity seems reliable, because both binding points will be distributed along the same regression line.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/90/11/1595/06 \$2.00

Volume 86, November 1990, 1595–1600

**Adipocyte measurements.** The fat cell volume and the number of fat cells incubated were determined as described previously (10).

**Preparation of nucleotides.** For solution hybridization analysis, total nucleic acids (TNA) were prepared by digestion of homogenized adipose tissue or fat cells with proteinase K in an SDS-containing buffer (1% SDS; 10 mmol/liter of Tris, pH 7.5; 5 mmol/liter of EDTA; protein kinase K, 100 mg/liter) and subsequent extraction with phenol-chloroform by the addition of isomylic ethanol (vol 24:1) (14). The concentration of nucleic acids was measured spectrophotometrically.

Northern blot analysis required ~ 20 g of subcutaneous adipose tissue, which was obtained during elective cholecystectomy on two male nonobese subjects (ages 47 and 50, respectively), but were otherwise healthy. The tissue was extracted as described above. Total RNA was prepared by the acid guanidinium thiocyanate method combined with the CsCl<sub>2</sub> centrifugation procedure (15). The amount of RNA was estimated from the optical density at 260 nm.

**Preparation of hybridization probes.** Complementary oligonucleotide probes (50 bases) were synthesized and hybridized to each other in a procedure described by Melton et al. (16). In addition, the hybrid contained recognition sequences for the restriction enzymes Pst I and Hind III. The constructions were cloned into the Pst I/Hind III sites in pGEM-3 (Promega Biotec., Madison, WI). The sequences of these insertions were confirmed by DNA sequencing using the dideoxy chain-termination method (17). The plasmid was employed for *in vitro* synthesis of cRNA using SP6 RNA polymerase, and for the opposite mRNA strand using T7 RNA polymerase. For solution hybridization analysis, the probes were radiolabeled with [<sup>35</sup>S]UTP, and for Northern blot analysis [<sup>32</sup>P]UTP was used. The sequence of the oligonucleotides used was for the beta-1-adrenergic receptors (nucleotides 739–789) (18), 5'GTG TTC CGC GAG GCC CAG AAG CAG GTG AAG AAG ATC GAC AGC TGC GAG CGC 3'; and for the beta-2-adrenergic receptor, (nucleotides 772–822) (19), 5'CTC CGC AGA TCT TCC AAG TTC TGC TTG AAG GAG CAC AAGCC CTC AAG ACG 3'. As a methodological control we employed a <sup>35</sup>S-labeled cDNA probe encoding the beta-actin (20).

**Northern blot hybridization.** This assay was performed essentially as described by Maniatis et al. (7). RNA samples (20–30 µg) were denatured for 10 min at 65°C in dimethylsulphoxide (50%), formaldehyde (2.2 mol/liter), sodium phosphate (10 mmol/liter, pH 7.5), EDTA (0.5 mmol/liter), and then electrophoresed through an agarose gel (1.2%) containing formaldehyde (2.2 mol/liter) in sodium phosphate (10 mmol/liter, pH 7.5) for 500 V-h in a running buffer containing morpholinopropane sulphonic acid (0.04 mmol/liter, pH 7.4), sodium acetate (10 mmol/liter), and EDTA (1 mmol/liter). The integrity of RNA samples was verified after gel electrophoresis by ethidium bromide staining. After two 30-min equilibrations in 20× SSC (3 mol/liter of NaCl, 0.3 mol/liter of sodium citrate), the RNA was transferred by the Southern technique to hybrid-N filters (Amersham Corp., Buckinghamshire, UK). Nylon membranes to which RNA had been transferred, were then prehybridized for 2 h at 55°C in 50% formamide, 5× SSC (1.0 mol/liter of NaCl, 0.1 mol/liter of sodium citrate), 5× Denhardt's solution (0.02% of Ficoll, 0.02% of polyvinyl pyrrolidone, and 0.02% of bovine serum albumin), 5 mmol/liter of phosphate buffer (pH 6.5), 5 mmol/liter of SDS, and 200 µg/ml of salmon testis DNA. Hybridization was carried out for 40 h at 55°C in an identical solution containing 4–6 × 10<sup>2</sup> cpm/ml of <sup>32</sup>P-labeled cRNA probe. After hybridization, the filter was washed serially with 0.1× SSC and 0.1% of SDS at 68°C to eliminate non-specific binding of the probes to the filter and ribosomal RNA. Autoradiographs were obtained by exposure to Kodak XAR-5 film with an intensifying screen for 48 h at 70°C. Molecular weight standards corresponding to RNA species of 28S and 18S were prepared from MCF7 cells. RNA for BAR<sub>1</sub> and BAR<sub>2</sub> were electrophoresed on the same gel and blotted over to the same filter. The filter was cut into different lanes for subsequent hybridization to either the BAR<sub>1</sub> probe or the BAR<sub>2</sub> probe.

**Solution hybridization.** This assay was carried out mainly as described previously (21). Briefly, [<sup>35</sup>S]UTP cRNA was hybridized

(20,000 cpm/sample) at 70°C to TNA samples. RNA hybrids were allowed to form in a buffer consisting of 0.6 mol/liter of NaCl, 30 mmol/liter of Tris HCL (pH 7.5), 5 mmol/liter of EDTA, 0.1% SDS, 10 mmol/liter of dithiothreitol, and 25% of formamide. After an overnight incubation, samples were treated with RNase for 45 min at 37°C by adding 1 ml of a solution containing 40 µg RNase A and 2 µg RNase T1 (both from Boehringer-Mannheim, Mannheim, FRG). RNase-resistant radioactivity was precipitated by the addition of 0.1 ml of trichloro acetic acid (6 mol/liter) and collected on glass fiber filters (Whatman Inc., Clifton, NJ). Sample TNA hybridization was compared with a known amount of an *in vitro* synthesized mRNA strand (complementary to the radioactive probe). A standard curve (0.5–30 × 10<sup>-8</sup> mol mRNA/incubation) was included in each assay. Each TNA sample was analyzed in duplicate and the amount of BAR<sub>1</sub> mRNA or BAR<sub>2</sub> mRNA was related to the amount of DNA in the TNA sample. Results are expressed as molecules/cell, assuming a content of 6.4 pg of DNA/adipocyte.

**Statistical methods.** The values presented are means±SE. Regression analysis, the F-distribution *t* test for comparing two regression lines and the paired and unpaired *t* tests were used for statistical comparison of the results.


## Results

**Adipose cellularity.** Adipocytes from the gluteal region were larger than those from the abdominal region, the adipocyte volume being 572±27 pl vs. 453±27 pl (*P* < 0.001). Moreover, the fat cells from males were somewhat smaller than those from women in both regions. These data confirm the results from several laboratories, including a recent study done by us (9).

**Radioligand binding.** The binding of labeled beta-adrenoceptor ligand was significantly increased in abdominal adipocytes as compared with gluteal adipocytes (Fig. 1). This was true when two concentrations of the radioligand <sup>3</sup>HCGP were used (in all subjects) as well as in the saturation experiments with <sup>125</sup>ICYP binding (six subjects).

If the results using the two different concentrations of each radioligand are representative of complete saturation experiments, they indicate that the number of beta-adrenoceptor binding site is almost twice as high in abdominal adipocytes as in gluteal adipocytes. Moreover, the Scatchard analysis of complete saturation experiments with <sup>125</sup>ICYP displayed straight and parallel lines for binding to both abdominal and gluteal cells. This shows that there was no difference between the two sites in adrenoceptor affinity for the radioligand. The Scatchard analysis also demonstrated that the maximum binding capacity of <sup>125</sup>ICYP was almost twice as high in abdominal as in gluteal adipocytes (*P* < 0.01). Thus, there was an almost twofold difference between abdominal and gluteal cells in the number of beta-adrenoceptors. The sex of the subjects had no significant effect on beta-adrenoceptor binding (data not shown). The binding data were expressed per cell number. The regional differences in binding were even more marked when expressed per cell surface area. The findings with BAR binding confirm previous results from our laboratory concerning gluteal and abdominal human adipocytes (9).


**Measurements of mRNA.** In this study we used cRNA probes derived from synthetic oligonucleotides (50 bases) in order to quantify specific BAR 1 and BAR 2 mRNA species. The sequences of the probes were obtained from published sequences and were confirmed by DNA sequencing. The hybridization conditions in the assay were determined from an analysis of the melting point of RNA-RNA hybrids (data not



**Figure 1.** Specific binding of beta-adrenergic antagonist radioligands to isolated subcutaneous fat cells from the abdominal (*open symbols*) or gluteal (*filled or hatched symbols*) region. The upper panel shows the results using two concentrations of the hydrophilic ligand  $^3\text{H-CGP}$  in 32 subjects. The results were statistically compared using the Student's paired *t* test.  $**P < 0.01$ ;  $***P < 0.001$ . The lower panels show Scatchard analysis of the results obtained from saturation experiments with adipocytes from three women and three men, using the lipophilic ligand  $^{125}\text{I-CYP}$ . Regression lines for abdominal and gluteal fat cells were statistically compared using the F-distribution test. Values are mean  $\pm$  SE.


shown). In order to confirm that the probes detected the correct transcripts, methodological experiments were carried out. The specificity of the probes for detecting BAR 1 and BAR 2 mRNA in total RNA extracts from human adipose tissue was tested by Northern blot analysis (Fig. 2). RNA was subjected to blot analysis and probed with the BAR 1 and the BAR 2 probe. The BAR<sub>1</sub> probe hybridized to an mRNA species of  $\sim 2.5$  kb and the BAR<sub>2</sub> probe to an mRNA species of  $\sim 2.2$  kb; these are mRNA species similar in size to those previously reported for BAR<sub>1</sub> and BAR<sub>2</sub> (18, 19). Another set of experiments (Fig. 3) showed that there was no cross-hybridization between the BAR 1 cRNA probe and in vitro synthesized mRNA complementary to the BAR 2 cRNA probe, and vice versa. These methodological data suggest that these probes specifically detect BAR 1 and BAR 2 mRNA.

The steady-state levels of BAR 1 and BAR 2 mRNA in the different adipose regions are indicated in Fig. 4. The expression of BAR 1 and BAR 2 mRNA was twice as high in the abdominal as in the gluteal area ( $P < 0.001$ ). The values for BAR 1 mRNA (molecules/cell) were  $47 \pm 1$  in abdominal isolated fat cells and  $20 \pm 1$  in gluteal adipocytes. Corresponding values for BAR 2 mRNA were  $29 \pm 2$  and  $16 \pm 2$  in abdominal and gluteal cells, respectively. Almost identical results were obtained with isolated fat cells and segments of adipose tissue. It was also noted that the level of expression of BAR<sub>1</sub> mRNA was higher than that of BAR<sub>2</sub> mRNA. This difference was statistically significant ( $P < 0.01$ ). However, there was no regional difference in this respect. The ratio of BAR 1 to BAR 2 mRNA in adipose segments was  $1.7 \pm 0.1$  for the abdominal site and  $1.6 \pm 0.1$  for the gluteal site. Similar results were obtained with isolated fat cells (data not shown).




**Figure 2.** Northern blot analysis of RNA from human adipose tissue. Two samples (each containing  $20 \mu\text{g}$  of total RNA) were electrophoresed on the same gel and blotted to the same nylon filter which was cut into two parts. Each half was subjected to RNA blot analysis and probed with  $^{32}\text{P}$ -labeled BAR<sub>1</sub> or BAR<sub>2</sub> cRNA probes as described in Methods. Positions of RNA markers are indicated. One experiment out of two is depicted.

In methodological studies, mRNA for beta-actin was measured in adipose segments of six men and six women. In women, the values (molecules/cell) were  $75 \pm 8$  and  $73 \pm 8$  in the abdominal and gluteal regions, respectively. The corresponding values in men were  $69 \pm 9$  and  $76 \pm 12$ . Thus, beta-actin mRNA showed no sex or regional variation.



**Figure 3.** Specificity of the cRNA probes in the solution hybridization assay. In vitro synthesized mRNA strand, corresponding to the cRNA probes for BAR<sub>1</sub> and BAR<sub>2</sub> was prepared. Increasing volumes, shown in the figure, of standard solutions of the two synthetic mRNA strands were added to a hybridization solution containing either  $^{32}\text{P}$ -labeled BAR<sub>1</sub> or BAR<sub>2</sub> cRNA. Solution hybridization was carried out as described in the text.



**Figure 4.** Expression of BAR<sub>1</sub> and BAR<sub>2</sub> mRNA in abdominal (open bars) or gluteal (hatched bars) adipose tissue. 32 men and women were investigated. mRNA was determined in isolated fat cells (left part) and in segments of adipose tissue. See legend to Fig. 1 for more details.

In order to determine if there was any sex difference in gene expression of BAR 1 and BAR 2, we compared mRNA in men and women. Fig. 5 shows the results with isolated fat cells. In both regions, the values for the two BAR mRNA species for men and women were almost identical. Similar results were found when adipose tissue segments were analyzed (data not shown).


In Figs. 4 and 5 the mRNA content was related to DNA (i.e., molecules/cells). In uncharted experiments mRNA was also related to TNA and is expressed as mol of mRNA/ $\mu$ g of TNA. These results were essentially the same as those obtained when DNA was used as the denominator.

In order to determine whether there existed any regional differences in mRNA stability, adipose tissue segments were incubated *in vitro* with the RNA polymerase inhibitor actinomycin D (Fig. 6). mRNA for BAR 1 and BAR 2 declined as a function of time (semilogarithmic relationship). However, there was no difference in the rate of decline between the two mRNA species or between regions. The apparent half-life of both mRNA species was  $\sim 6$  h.


## Discussion

In this study, the possible functional importance of BAR gene expression has been investigated for the first time in man. The expression of receptor protein may be regulated at both the transcriptional and the posttranscriptional levels. The latter includes effects on mRNA stability, translation efficiency, protein turnover, or a modification of the protein that alters its biological activity.

Our study shows that the BAR receptor number is higher in abdominal than in gluteal adipocytes of men and women. This is in consonance with our earlier study (9). Since we also measured mRNA levels for the genes that encode for BAR, it is possible to understand the molecular mechanisms that may be responsible for the variations in BAR expression between different types of adipocytes for the first time.



**Figure 5.** Influence of sex on the expression of BAR<sub>1</sub> and BAR<sub>2</sub> mRNA in isolated subcutaneous fat cells from the abdominal (left) or gluteal (right) region. The findings in nine men (filled bars) and seven women (hatched bars) were compared. Values are mean  $\pm$  SE.



**Figure 6.** Stability of mRNA for BAR<sub>1</sub> and BAR<sub>2</sub> in different regions of subcutaneous adipose tissue from different regions. Segments of adipose tissue were incubated in the presence or absence of actinomycin D (5  $\mu$ g/ml) and mRNA was determined after 0, 2, 4, and 6 h of incubation. Actinomycin values were corrected for control values and expressed as a percentage of initial values. One experiment of two (both show similar results) is depicted. Symbols are given in the text.

The steady-state mRNA levels for BAR 1 and for BAR 2 were about twice as high in abdominal as in gluteal fat cells. This corresponded well with the twofold difference in cell surface BAR number between the two cell types that were also observed in this study. Because of the limited amount of tissue available, we could not determine the proportions of BAR 1 and BAR 2 binding sites in the two adipose regions. Therefore, it is not known at present whether regional differences in BAR number involve both receptor subtypes or only one receptor subtype. Basal mRNA levels of BAR have previously proved to be in agreement with the levels of these receptor subtypes, as determined by radioligand binding techniques in different rat tissues (18). This study indicates that measurement of BAR mRNA levels by solution hybridization in human adipose tissue accords well with determination of BAR by ligand binding. Thus, the observed increase in BAR mRNA expression in abdominal adipocytes may be the major reason why these cells have a higher number of cell surface BAR than gluteal adipocytes have.

It is unlikely that the site difference in BAR mRNA is due to a general increase in mRNA in abdominal tissue as compared with gluteal tissue, since the amounts of beta-actin mRNA were almost identical in cells from both regions. Moreover, the regional variations in BAR mRNA cannot be attributed to stroma cells, as similar results were obtained with adipose segments and with isolated fat cells.

The site differences in BAR mRNA levels can scarcely be due to variations in mRNA stability. The apparent half-lives of BAR 1 and BAR 2 mRNA in segments of isolated adipose tissue were similar in both regions, as evidenced by the results of experiments using actinomycin D. These results may indicate that site variations in BAR mRNA levels are due to differences in the gene transcription rate. However, the mRNA half-life is only an indirect indicator of transcription. In addition, actinomycin D in itself may influence mRNA metabolism. Unfortunately, it was not possible to directly measure the transcription rate of the BAR genes in the small amount of human adipose tissue that was available in our study.

It has been demonstrated earlier that regional differences in catecholamine-induced lipolysis are more apparent in women than in men (5, 9). There are, however, no sex variations in

beta-adrenoceptor-mediated lipolytic effects in fat cells from the two regions (9). This agrees with the present findings that show no influence of sex on BAR number or BAR 1 and BAR 2 mRNA expression.

Adenylate cyclase-linked receptors, such as the BAR subtype, are low abundance proteins with low basal levels of corresponding mRNAs (22, 23). Therefore, it is not possible to measure these mRNA levels in small amounts of human adipose tissue with the standard quantitative Northern blot analysis because this method has low sensitivity. In this study, we measured mRNA levels using a very sensitive solubilization hybridization assay. Previously, BAR 2 mRNA has been determined in hamster DDT<sub>1</sub> MF-2-cells using this technique (22, 23). The steady-state levels of BAR 2 mRNA appear to be in the same order of magnitude in these hamster cells as in human fat cells.

Although BAR<sub>1</sub> and BAR<sub>2</sub> are encoded by different genes, previous studies have indicated similarities among BAR subtypes in immunological and photoaffinity labeling properties as well as in the SDS-polyacrylamide gel electrophoresis migration pattern ( $M_r = 65,000-67,000$ ) for both receptor subtypes (24). These data suggest that the molecular basis for the subtype specificity of BAR may be due to posttranslational modification. However, studies by Babouth et al. (25) and Strader et al. (26), using a cDNA probe for the hamster BAR<sub>2</sub>, indicated that posttranslational modification of the receptor by a cell in which it is expressed does not dictate subtype specificity. We also found that the size of the mRNA species encoding for the BAR<sub>1</sub> (2.5 kb) was larger than that encoding for the BAR<sub>2</sub> (2.2 kb). This confirms previous results in other tissues (18, 19) and indicates an important structural difference between the two mRNA species in human fat cells. Thus, it seems likely that in human fat cells the subtype character of the BAR is the result of the expression of separate but homogeneous genes. Recently, a BAR<sub>3</sub> gene has been isolated in man (27). Whether this gene is also expressed in human fat cells remains to be established.

Our results indicate that the specific regulation of BAR subtype expression in human adipose tissue involves transcriptional rather than posttranscriptional mechanisms. The results of recent studies indicate that hormones which are important for fat cells, such as catecholamines and glucocorticoids, can alter transcription of BAR genes resulting in corresponding changes of the steady-state BAR mRNA levels (28, 29). Thus, the presently observed regional difference in mRNA levels for BAR<sub>1</sub> and BAR<sub>2</sub> may be due to variations in the action of hormones or other regulatory agents on BAR gene transcription in adipocytes from different fat depots. However, posttranscriptional regulation of BAR protein expression in fat cells must be considered as well. It has recently been demonstrated that catecholamines have posttranscriptional effects on BAR mRNA levels. These hormones seem to promote destabilization of mRNA (30).

In fat cells of either sex or region, the basal BAR<sub>1</sub> mRNA levels were ~ 50% higher than the BAR<sub>2</sub> mRNA levels. This was not due to any differences in RNA stability, as judged by the experiments with actinomycin D. The latter may indicate that there is a variation in gene transcription activity between the BAR subtypes in human fat cells. The functional importance of the observed difference in mRNA expression of BAR<sub>1</sub> and BAR<sub>2</sub> is not known at present since, for reasons discussed previously, we were not able to determine the number of each

receptor subtype in this study. However, previous studies from our laboratory suggest that the proportion of BAR<sub>1</sub> relative to BAR<sub>2</sub> binding sites in intact human fat cells is 4 to 1 (10). We have also found that the lipolytic order of potency for catecholamines in isolated human fat cells indicates a preponderance of BAR<sub>1</sub> (31). Thus, previous functional studies from our own laboratory regarding the two BAR subtypes are in agreement with the present mRNA data.

In the Northern blot analyses (Fig. 2), the mRNA signals for BAR<sub>1</sub> and BAR<sub>2</sub> were of similar strengths, which may seem at odds with the solution hybridization data. It should, however, be stressed that the Northern blot experiments were not designed to be quantitative. Instead they were used to test the specificity of the probes and to investigate the size of each mRNA species. Neither the amount of RNA that was blotted nor the hybridization conditions were standardized in the rigorous way that is necessary for quantitative Northern blot analysis.

In summary, abdominal adipocytes have more BAR binding sites than do fat cells from the gluteal area in men and women. This can be explained by an increased expression of the genes that encode for BAR 1 and BAR 2 in the former cells. This difference in gene expression constitutes a molecular mechanism for regional variations in adipocyte lipolysis activity.

## Acknowledgments

This study was supported by grants from the Swedish Medical Research Council (19K-08714), Draco AB (Lund, Sweden), the Swedish Diabetes Association, Swedish Athletes Research Council, Swedish Medical Association, Swedish Cancer Society, Karolinska Institute, and the Foundations of Osterman, Nordic Insulin, Stohne, and Old Female Servants.

## References

1. Marcus, C., B. Ehrén, P. Bolme, and P. Arner. 1988. Regulation of lipolysis during the neonatal period. Importance of thyrotropin. *J. Clin. Invest.* 82:1793-1797.
2. Kather, H., K. Zöllig, B. Simon, and G. Schlierf. 1977. Human fat cell adenylate cyclase: regional differences in adrenaline responsiveness. *Eur. J. Clin. Invest.* 7:595-597.
3. Smith, U., J. Hammarstein, P. Björntorp, and J. G. Kral. 1979. Regional differences and effect of weight reduction on human fat cell metabolism. *Eur. J. Clin. Invest.* 9:327-332.
4. Lafontan, M., L. Dang-Tran, and M. Berlan. 1979. Alpha-adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenaline responsiveness of different fat deposits. *Eur. J. Clin. Invest.* 9:261-266.
5. Leibel, R., and J. Hirsch. 1987. Site- and sex-related difference in adrenoceptor status of human adipose tissue. *Metab. Clin. Exp.* 28:1198-1205.
6. Arner, P. 1988. Control of lipolysis and its relevance to development of obesity in man. *Diabetes Metab. Rev.* 4:505-507.
7. Björntorp, P. 1987. Fat cell distribution and metabolism. *Ann. NY. Acad. Sci.* 499:66-72.
8. Smith, U. 1985. Regional differences in adipocyte metabolism and possible consequences in vivo. *Int. J. Obesity.* 9:145-148.
9. Wahrenberg, H., F. Lönnqvist, and P. Arner. 1989. Mechanisms underlying regional differences in lipolysis in human adipose tissue. *J. Clin. Invest.* 84:458-467.
10. Engfeldt, P., P. Arner, H. Wahrenberg, and J. Östman. 1982. An assay for beta-adrenergic receptors in isolated human fat cells. *J. Lipid Res.* 23:715-719.

11. Mauriége, P., G. DePergola, M. Berlan, and M. Lafontan. 1988. Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta<sub>1</sub>-antagonists. *J. Lipid Res.* 29:587-601.
12. Engfeldt, P., J. Hellmér, H. Wahrenberg, and P. Arner. 1984. Effects of insulin on adrenoceptor binding and the rate of catecholamine-induced lipolysis in isolated human fat cells. *J. Biol. Chem.* 263:15553-15560.
13. Wahrenberg, H., F. Lönnqvist, P. Engfeldt, and P. Arner. 1989. Abnormal action of catecholamines on lipolysis in adipocytes of type I diabetic patients treated with insulin. *Diabetes.* 38:524-533.
14. Durham, D. M., and R. P. Palmiter. 1983. A practical approach for quantitating specific mRNAs by solution hybridization. *Anal. Biochem.* 131:385-393.
15. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
16. Melton, D. A., P. A. Kireg, M. R. Rebagliati, T. Maniatis, K. Zinn, and M. P. Green. 1984. Efficient in vitro synthesis of biologically-active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. *Nucleic Acids Res.* 12:7035-7056.
17. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463-5467.
18. Frielle, T., S. Collins, U. W. Daniel, M. G. Carn, R. J. Lefkowitz, and B. K. Kobilka. 1987. Cloning of the cDNA for the human beta<sub>1</sub>-adrenergic receptor. *Proc. Natl. Acad. Sci. USA.* 84:7920-7924.
19. Kobilka, T. L., R. A. F. Dixon, T. Frielle, H. G. Dohlman, M. A. Bolanowski, I. S. Sigal, T. L. Yang-Feng, U. Francke, M. C. Caron, and R. J. Lefkowitz. 1987. cDNA for the human beta<sub>2</sub>-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. *Proc. Natl. Acad. Sci. USA.* 84:46-50.
20. Cleveland, D. N., M. N. Lopata, R. J. MacDonald, N. J. Lewan, W. J. Rutter, and M. W. Kirschner. 1980. Number and evolutionary conservation of alpha- and beta-tubulin and cytoplasmic beta- and gamma-actin genes using specific cloned cDNA probes. *Cell.* 20:95-105.
21. Brönnegård, M., O. Andersson, D. Edwall, J. Lund, G. Norstedt, and J. Carlstedt-Duke. 1988. Human calpactin II (lipocortin I) messenger ribonucleic acid is not induced by glucocorticoids. *Mol. Endocrinol.* 2:732-739.
22. Hadcock, J. R., and C. C. Malbon. 1988. Regulation of beta-adrenergic receptors by "permissive" hormones: glucocorticoids increase steady-state levels of receptor mRNA. *Proc. Natl. Acad. Sci. USA.* 85:8415-8419.
23. Hadcock, J. R., and C. C. Malbon. 1988. Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels. *Proc. Natl. Acad. Sci. USA.* 85:5021-5025.
24. Lefkowitz, R. J., and M. G. Caron. 1988. Adrenergic receptor models for the study of receptors coupled to guanine nucleotide regulatory proteins. *J. Biol. Chem.* 263:4993-4996.
25. Bahouth, S. W., J. R. Hadcock, and C. C. Malbon. 1988. Expression of mRNA of beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptors in Xenopus oocytes results from structurally distinct receptor mRNAs. *J. Biol. Chem.* 263:8822-8826.
26. Strader, C. D., M. R. Candelore, E. Rands, and R. A. F. Dixon. 1987. Adrenergic receptor subtype is an intrinsic property of the receptor gene product. *Mol. Pharmacol.* 32:179-183.
27. Emorine, L. J., S. Marullo, M. B. Briend-Sutren, G. Patey, K. Tate, C. Delavier-Klutchko, and A. D. Strosberg. 1989. Molecular characterization of the human beta<sub>3</sub>-adrenergic receptor. *Science (Wash. DC).* 245:1118-1121.
28. Collins, S., M. G. Caron, and R. J. Lefkowitz. 1988. Beta<sub>2</sub>-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. *J. Biol. Chem.* 263:9067-9070.
29. Collins, S., M. Bouvier, M. A. Bolanowski, M. G. Caron, and R. J. Lefkowitz. 1989. cAMP stimulates transcription of the beta<sub>2</sub>-adrenergic receptor genes in response to short-term agonist exposure. *Proc. Natl. Acad. Sci. USA.* 86:4853-4857.
30. Hadcock, J. R., H. Wang, and C. Malbon. 1989. Agonist-induced destabilization of beta-adrenergic receptor mRNA. *J. Biol. Chem.* 264:19928-19933.
31. Marcus, C., B. Karpe, P. Bolme, T. Sonnenfeld, and P. Arner. 1987. Changes in catecholamine-induced lipolysis in isolated human fat cells during the first year of life. *J. Clin. Invest.* 79:1812-1818.